. Author manuscript; available in PMC: 2014 Dec 1.

Published in final edited form as: Leukemia. 2014 Jan 23;28(6):1365–1368. doi: 10.1038/leu.2014.42

Table 1.

Pretreatment Characteristics of Chronic Lymphocytic Leukemia Patients with del(17p) Karyotype Evaluated at Ohio State University

Characteristic	Overall N=174	Ibrutinib N = 27	CDKi N = 58	Other N = 89	P^*

Median Age, years	63	64	63	63	0.60
Range	39-83	50-77	39-81	42-83

Female Sex, no. (%)	60 (34)	8 (30)	16 (28)	36 (40)	0.25

White Race, no. (%)	160 (93)	25 (93)	55 (95)	80 (92)	0.85
Unknown	2	0	0	2

Rai Stage, no. (%)					1.00
0/I/II	49 (29)	8 (30)	17 (29)	24 (28)
III/IV	121 (71)	19 (70)	41 (71)	61 (72)
Unknown	4	0	0	4

ECOG PS, no. (%)					0.12
0/1	150 (89)	26 (96)	53 (93)	71 (84)
2/3	19 (11)	1 (4)	4 (7)	14 (16)
Unknown	5	0	1	4

Prior Therapies ≥3, no. (%)	93 (53)	19 (70)	37 (64)	37 (42)	0.005

Median Prior Treatments, no.	3	4	3	2	0.001
Range	1-10	1-9	1-10	1-7

Median WBC Count, × 10⁹/L	17.9	18.8	12.1	25.5	0.04
Range	0.4-289.1	1.3-289.1	1.2-144.5	0.4-287.0
Unknown	7	0	0	7

Median Creatinine, mg/dL	0.95	1.06	0.94	0.96	0.09
Range	0.47-2.70	0.47-2.09	0.47-1.76	0.50-2.70
Unknown	13	0	0	13

Median Albumin, g/dL	3.8	3.8	3.9	3.8	0.80
Range	1.9-5.0	2.6-4.8	2.7-4.5	1.9-5.0
Unknown	18	0	1	17

Median LDH^†, U/L	221	200	221	235	0.11
Range	78-1091	120-1091	97-687	78-1007
Unknown	17	0	0	17

Median 17p, %	74	74	70	77	0.44
Range	6-100	7-99	6-97	6-100

FISH^‡, no. (%)
Del(11q)	36 (21)	8 (30)	15 (26)	13 (15)	0.10
Del(13q)	100 (57)	16 (59)	34 (59)	50 (56)	0.93
Trisomy 12	28 (16)	6 (22)	9 (16)	13 (15)	0.66

CK, no. (%)	121 (70)	22 (81)	38 (66)	61 (69)	0.32

P-values result from testing the association between treatment group and categoric or continuous variables, respectively, using Fisher's exact or the non-parametric Kruskal-Wallis test.

^†

Upper limit of normal LDH is 190 U/L.

^‡

Aberrations are not mutually exclusive.

LDH=lactate dehydrogenase; WBC=white blood cell; PS=performance status; CK=complex karyotype.